title: Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance.
abstract: Cancer patients selected for cisplatin-based chemotherapy were randomly divided into two groups (42 patients in each) which received either metoclopramide or ondansetron as antiemetics. Metoclopramide was given i.v. with 5 doses of 2 mg/kg starting 30 min before the cisplatin infusion and continued with one dose every 3 h. Ondansetron was given with a first injection of 8 mg i.v. 30 min before the cisplatin infusion; the patients were given 8 mg orally 5 and 10 h after the cisplatin infusion followed by 8 mg x 3 during the next two days. In the present study ondansetron was superior to metoclopramide concerning antiemetic efficacy and gave also less side-effects as diarrhea, dizziness, extrapyramidal symptoms and electrolyte imbalance (sodium, potassium, magnesium, phosphorous) during the first 24 h following the cisplatin infusion.
authors.affiliation: Second Department of Medical Oncology, METAXA Cancer Hospital, Piraeus, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Tsavaris
authors.forename: G
authors.initials: G
authors.lastname: Charalambidis
authors.forename: N
authors.initials: N
authors.lastname: Ganas
authors.forename: M
authors.initials: M
authors.lastname: Pagou
authors.forename: A
authors.initials: A
authors.lastname: Karabellis
authors.forename: N
authors.initials: N
authors.lastname: Mylonakis
authors.forename: N
authors.initials: N
authors.lastname: Benou
authors.forename: D
authors.initials: D
authors.lastname: Tsikalakis
authors.forename: P
authors.initials: P
authors.lastname: Kosmidis
mesh_terms: D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy; D017294:Ondansetron / Q000627:therapeutic use*; D011446:Prospective Studies; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced*
chemical_list: D017294:Ondansetron; D008787:Metoclopramide; D002945:Cisplatin